PharmaCyte Biotech, Inc. (PMCB)
Nasdaq: PMCB · Biological Products, (No Diagnostic Substances) · Las Vegas, NV · filing with the SEC since 2001
Filings
203 filings since 2017 beside 46 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company
10-Q
Quarterly report for the quarter ending Oct 31, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by Dec 15, 2026
10-K
Annual report for the fiscal year ending Apr 30, 2027Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Jul 29, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. The proxy statement was last filed Mar 9, 2026.
Filings a yearinsider forms included
910415044203321
2026 counts to Nov 13, 2026.
Auditor change (8-K item 4.01): 2 times in the last 36 months, the newest Oct 16, 2026.Officer or director change (8-K item 5.02): 3 times in the last 36 months, the newest Apr 2, 2026.Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest Dec 5, 2025.SEC letters: 2 in the last 36 months, the newest Sep 24, 2025.A late-filing notice, Form NT 10-Q, filed Dec 15, 2025.A late-filing notice, Form NT 10-K, filed Jul 29, 2025.A late-filing notice, Form NT 10-Q, filed Sep 17, 2024.A late-filing notice, Form NT 10-K, filed Jul 29, 2024.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Apr 2, 2026
8-K items 5.02, 5.07, 9.01
Officer or director change; Shareholder vote · Current report
Mar 30, 2026
Nov 18, 2025
8-K/A item 9.01
Financial statements and exhibits · Current report, amended
Sep 2, 2025
Oct 31, 2025
8-K items 5.02, 5.07, 9.01
Officer or director change; Shareholder vote · Current report
Oct 30, 2025
Sep 5, 2025
8-K items 1.01, 2.01, 7.01, 9.01
Major agreement signed; Purchase or sale of a business completed; Investor disclosure (Regulation FD) · Current report
Sep 2, 2025
Aug 18, 2025
8-K items 1.01, 3.02, 7.01, 9.01
Major agreement signed; Shares sold without registration; Investor disclosure (Regulation FD) · Current report
Aug 17, 2025
40 of 203 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.